Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes respiratory conditions such as asthma — as a monotherapy and as part of novel drug combinations.
The post AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge appeared first on MedCity News.
